References


  1. Abdolrasulnia M, Shewchuk RM, Roepke N, Granstaff US, Dean J, Foster JA, Goldstein AT, Casebeer L. Management of female sexual problems: perceived barriers, practice patterns, and confidence among primary care physicians and gynecologists. J Sex Med. 2010;7(7):2499-2508.
  2. Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril . 2017 Feb;107(2):475-482.e15.
  3. Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, Mimoun S, Nappi RE, Palacios S, Schwenkhagen A, Studd J, Wylie K, Zahradnik HP. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 2010;13(2):103-120. Review.
  4. Althof S, Lucas J, Rosen R, Jordan R, Greenberg S, DeRogatis LR. Responder Analyses Based on Minimum Clinically Important Differences Derived from Receiver Operating Characteristic Curves in Premenopausal Women Using Bremelanotide for Female Sexual Dysfunctions. 1: USA .
  5. Anderson JL. Acknowledging female sexual dysfunction in women with cancer. Clin J Oncol Nurs. 2013;17(3):233-235.
  6. Anis TH, Gheit SA, Saied HS, Al kherbash SA. Arabic translation of Female Sexual Function Index and validation in an Egyptian population. J Sex Med. 2011;8(12):3370-3378.
  7. Aubert Y, Bohl MA, Lange JR, Diol NR, Allers KA, Sommer B, Datson NA, Abbott DH. Chronic systemic administration of serotonergic ligands flibanserin and 8-OH-DPAT enhance HPA axis responses to restraint in female marmosets. Psychoneuroendocrinology. 2013;38(1):145-154.
  8. Aubert Y, Gustison ML, Gardner LA, Bohl MA, Lange JR, Allers KA, Sommer B, Datson NA, Abbott DH. Flibanserin and 8-OH-DPAT implicate serotonin in association between female marmoset monkey sexual behavior and changes in pair-bond quality. J Sex Med. 2012;9(3):694-707.
  9. Baldwin A, Dodge B, Schick V, Herbenick D, Sanders SA, Dhoot R, Fortenberry JD. Health and identity-related interactions between lesbian, bisexual, queer and pansexual women and their healthcare providers. Cult Health Sex . 2017 Nov;19(11):1181-1196.
  10. Basson R, Berman J, Burnett A, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163(3):888-893.
  11. Basson R, Brotto LA, Petkau AJ, Labrie F. Role of androgens in women's sexual dysfunction. Menopause. 2010;17(5):962-971.
  12. Belikin ZR, BS, Krapf JM, MD, Goldstein AT. Drugs In Early Clinical Development for the Treatment of Female Sexual Dysfunction. Expert Opinion on Investigational Drugs. 2014 Nov; 24(2).
  13. Berman L, Berman J, Felder S, et al. Seeking help for sexual function complaints: what gynecologists need to know about the female patient's experience. Fertil Steril. 2003;79(3):572-576.
  14. Bianchi-Demicheli F, Cojan Y, Waber L, Recordon N, Vuilleumier P, Ortigue S. Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study. J Sex Med. 2011;8(9):2546-2559.
  15. Biddle AK, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health . 2009 Jul-Aug;12(5):763-72.
  16. Bitzer J, Giraldi A, Pfaus J.Sexual desire and hypoactive sexual desire disorder in women. Introduction and overview. Standard operating procedure (SOP Part 1). J Sex Med. 2013;10(1):36-49.
  17. Bloemers J, Gerritsen J, Bults R, Koppeschaar H, Everaerd W, Olivier B, Tuiten A. Induction of sexual arousal in women under conditions of institutional and ambulatory laboratory circumstances: a comparative study. J Sex Med. 2010;7(3):1160-1176.
  18. Bloemers J, Scholte HS, van Rooij K, Goldstein I, Gerritsen J, Olivier B, Tuiten A. Reduced gray matter volume and increased white matter fractional anisotropy in women with hypoactive sexual desire disorder. J Sex Med. 2014;11(3):753-767.
  19. Bloemers J, van Rooij K, de Leede L, Frijlink HW, Kopperschaar HP, Olivier B, Tuiten A. Single dose sublingual testosterone tablet and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. Br. J Clin Pharmacol. 2016 Jun;81(6): 1091-102. Doi: 10.1111/bcp. 12887.
  20. Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, Chivers M, Gerritsen J, van Ham D, Olivier B, Tuiten A. Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for Hypoactive Sexual Desire Disorder and female sexual arousal disorder. J Sex Med. 2013;10(3):791-809.
  21. Bradford A. Listening to placebo in clinical trials for female sexual dysfunction. J Sex Med. 2013;10(2):451-459.
  22. Brauer M, van Leeuwen M, Janssen E, Newhouse SK, Heiman JR, Laan E. Attentional and Affective Processing of Sexual Stimuli in Women with Hypoactive Sexual Desire Disorder. 2012;41(4):891-905.
  23. Brotto LA. Evidence-based treatments for low sexual desire in women. Front Neuroendocrinol . 2017 Apr;45:11-17.
  24. Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch Sex Behav. 2010;39(2):221-239.
  25. Brotto LA, Petkau AJ, Labrie F, Basson R. Predictors of sexual desire disorders in women. J Sex Med. 2011;8(3):742-753.
  26. Burri A, Spector T, Rahman Q.  A Discordant Monozygotic Twin Approach to Testing Environmental Influences on Sexual Dysfunction in Women. Arch Sex Behav. 2013 Apr 20.
  27. Burri A, Spector T, Rahman Q. The etiological relationship between anxiety sensitivity, sexual distress, and female sexual dysfunction is partly genetically moderated. J Sex Med. 2012;9(7):1887-1896.
  28. Carvalheira AA, Brotto LA, Leal I. Women's motivations for sex: exploring the diagnostic and statistical manual, fourth edition, text revision criteria for hypoactive sexual desire and female sexual arousal disorders. J Sex Med. 2010;7(4 Pt 1):1454-1463.
  29. CAUSE Distinguished Faculty Web conference, conducted October 29, 2008. Participant post-activity evaluations and comments received from CIEF/CAUSE/TU initiative activities.
  30. Chen CH, Lin YC, Chiu LH, Chu YH, Ruan FF, Liu WM, Wang PH. Female sexual dysfunction: definition, classification, and debates. Taiwan J Obstet Gynecol. 2013;52(1):3-7.\
  31. Clayton AH. The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010;110(1):7-11. Review.
  32. Clayton AH, Althof S, Kingsberg S, DeRogatis L, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman D. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health (Lond) . 2016 Jun; 12(3): 325–337.
  33. Clayton AH, Althof SE, Kingsberg S, Derogatis L, Kroll R, Goldstein I, Kaminetsky K, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for Female Sexual Dysfunctions in Premenpausal Women: A Ramdomized, Placebo-Controlled Dose-Finding Trial. Women’s Health (Lond). 2016 Jun;12(3):325-337.
  34. Clayton AH, Croft H, Yuan J, Brown L, Kissling R. Safety of Flibanserin in Women Treated With Antidepressants: A Randomized, Placebo-Controlled Study. J Sex Med . 2018 Jan;15(1):43-51.
  35. Clayton AH, Dennerstein L, Pyke R, Sand M. Flibanserin: a potential treatment for Hypoactive Sexual Desire Disorder in premenopausal women. Womens Health (Lond Engl). 2010;6(5):639-653.
  36. Clayton AH, DeRogatis LR, Rosen RC, Pyke R. Intended or unintended consequences? The likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 2. For women with loss of subjective sexual arousal. J Sex Med. 2012;9(8):2040-2006.
  37. Clayton AH, Edelson J, Jordan R. Effect of Self-Administered Bremelanotide on Sexual Interest and Desire in Premenopausal Women With Female Sexual Dysfunctions. Poster. 167th Annual Meeting of the American Psychiatric Association . 2024 May 3-7.
  38. Clayton AH, Goldfischer E, Goldstein I, DeRogatis L, Nappi R, Lewis-D'Agostino DJ, Kimura T, Hebert A, Pyke R. Validity of the decreased sexual desire screener for diagnosing hypoactive sexual desire disorder. J Sex Marital Ther. 2013;39(2):132-143.
  39. Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D'Agostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6(3):730-738.
  40. Clayton AH, Goldmeier D, Nappi RE, Wunderlich G, Lewis-D'Agostino DJ, Pyke R. Validation of the sexual interest and desire inventory-female in hypoactive sexual desire disorder. J Sex Med. 2010;7(12):3918-3928.
  41. Clayton AH, Groth J. Etiology of female sexual dysfunction. Womens Health (Lond Engl). 2013;9(2):135-137.
  42. Clayton AH, Kingsberg SA, Goldstein I. Evaluation and Management of Hypoactive Sexual Desire Disorder. Sex Med Rev. 2018 Mar.
  43. Clayton AH, Kingsberg SA, Simon J, Jordan R, Lucas J. The Investigational Drug Bremelanotide for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses from the RECONNECT Studies. Poster presented at: 20th Annual NPWH Premier Women's Healthcare Conference. October 13, 2017; Seattle, WA.
  44. Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Co-administered With Ethanol in Health Male and Female Participants. Clin Ther. 2017 Mar;39(3):514.e14.
  45. Clayton AH, Lucas J, Jordan R, Spana C, Pfaus J. Bremelanotide: A Review of Its Neurobiology and Treatment Efficacy for HSDD. Poster. 20th World Meeting on Sexual Medicine . 2016 Sep 22.
  46. Clayton AH, Pyke RE. Is flibanserin meaningfully superior to placebo? J Sex Marital Ther . 2017 Nov 2.
  47. Clayton AH, Segraves RT, Bakish D, Goldmeier D, Tignol J, van Lunsen RH, Nappi RE, Wunderlich G, Kimura T, Lewis-D'Agostino DJ, Pyke R. Cutoff score of the sexual interest and desire inventory-female for diagnosis of hypoactive sexual desire disorder. J Womens Health (Larchmt). 2010;19(12):2191-2195.
  48. Clayton AH, Valladares Juarez EM, Female Sexual Dysfunction. Psychiatr Clin North Am. 2017 Jun;40(2):267-284.
  49. Clegg M, Towner A, Wylie K. Should questionnaires of female sexual dysfunction be used in routine clinical practice? Maturitas. 2012;72(2):160-164.
  50. Connor MK, Maserejian NN, De Rogatis L, Meston CM, Gerstenberger EP, Rosen RC. Sexual desire, distress, and associated factors in premenopausal women: preliminary findings from the hypoactive sexual desire disorder registry for women. J Sex Marital Ther. 2011;37(3):176-189.
  51. Cortelazzi D, Marconi A, Guazzi M, Cristina M, Zecchini B, Veronelli A, Cattalini C, Innocenti A, Bosco G, Pontiroli AE. Sexual dysfunction in pre-menopausal diabetic women: clinical, metabolic, psychological, cardiovascular, and neurophysiologic correlates. Acta Diabetol. 2013 May 16.
  52. Croft HA. Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options. J Sex Med . 2017 Dec;14(12):1575-1584.
  53. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005-2017.
  54. Davis SR, Worsley R. Androgen treatment of postmenopausal women. J Steroid Biochem Mol Biol. 2013 May 29.
  55. Davis SR. Should women receive androgen replacement therapy, and if so, how?  Clin Endocrinol (Oxf). 2010;72(2):149-154.
  56. De Franciscis P, Mainini G, Messalli EM, Trotta C, Luisi A, Laudando E, Marino G, Della Puca G, Cerreto FV, Torella M. Arterial hypertension and female sexual dysfunction in postmenopausal women. Clin Exp Obstet Gynecol. 2013;40(1):58-60.
  57. Dennerstein L, Hayes R, Sand M, Lehert P. Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J Sex Med. 2009;6(6):1668-1673.
  58. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med . 2006 Mar;3(2):212-22.
  59. DeRogatis L, Althof S, Clayton A, Jordan R, Lucas J, Changes in Arousal and Desire in the Bremelanotide RECONNECT Study. J Sex Med. 2017. 14(6): 356.
  60. Derogatis L, Edelson J, Revicki D. Reliability and Validity of the Female Sexual Distress Scale-Desire/Arousal/Orgasm Instrument in a Phase 2B Dose-Ranging Study of Bremelanotide. Poster. 167th Annual Meeting of the American Psychiatric Association . 2014 May 3-7.
  61. DeRogatis L, Pyke R, McCormack J, Hunter A, Harding G. Does the Female Sexual Distress Scale Revised cover the feelings of women with HSDD? J Sex Med. 2011;8(10):2810-2815.
  62. DeRogatis LR, Allgood A, Auerbach P, Eubank D, Greist J, Bharmal M, Zipfel L, Guo CY. Validation of a Women's Sexual Interest Diagnostic Interview--Short Form (WSID-SF) and a Daily Log of Sexual Activities (DLSA) in postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2010;7(2 Pt 2):917-927.
  63. Derogatis LR, Clayton AH, Goldstein A, Lewis-D'Agostino D, Wunderlich G, Cotton D. eDiary and Female Sexual Distress Scale(©) in evaluating distress in hypoactive sexual desire disorder (HSDD). J Sex Res. 2011;48(6):565-572.
  64. Derogatis LR, Komer L, Katz M, Moreau M, Kimura T, Garcia M Jr, Wunderlich G, Pyke R; VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012;9(4):1074-1085.
  65. DeRogatis LR. Consultation corner. The latest on female sexual health. Johns Hopkins Med Lett Health After 50. 2010;22(9):6-7.
  66. de Souza KZ, Vale FB, Geber S Efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women: a randomized, double-blinded, placebo-controlled trial. Menopause . 2016 Nov;23(11):1252-1256.
  67. Dhanuka I, Simon JA. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Expert Opin Pharmacother . 2015;16(16):2523-9.
  68. Dhingra C, Kellogg-Spadt S, McKinney TB, Whitmore KE. Urogynecological causes of pain and the effect of pain on sexual function in women. Female Pelvic Med Reconstr Surg. 2012;18(5):259-267.
  69. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med . 2006 Jul;3(4):628-638.
  70. Dimitropoulos K, Bargiota A, Mouzas O, Melekos M, Tzortzis V, Koukoulis G. Sexual functioning and distress among premenopausal women with uncomplicated type 1 diabetes. J Sex Med. 2012;9(5):1374-1381.
  71. Dooley EM, Miller MK, Clayton AH. Flibanserin: From Bench to Bedside. Sex Med Rev . 2017 Oct;5(4):461-469.
  72. Dunn ME. Restoration of couple's intimacy and relationship vital to reestablishing erectile function. J Am Osteopath Assoc. 2004;104(3 Suppl 4):S6-10.
  73. Echeverry MC, Arango A, Castro B, Raigosa G. Study of the prevalence of female sexual dysfunction in sexually active women 18 to 40 years of age in Medellín, Colombia. J Sex Med. 2010;7(8):2663-2669.
  74. Elsamra S, Nazmy M, Shin D, Fisch H, Sawczuk I, Fromer D. Female sexual dysfunction in urological patients: findings from a major metropolitan area in the USA. BJU Int. 2010;106(4):524-526.
  75. English C, Muhleisen A, Rey JA, Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women. PT . 2017 Apr; 42(4):237-241.
  76. Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res. 2005;17(3):224-226.
  77. Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):179-184.
  78. Fabre LF, Smith LC. The effect of major depression on sexual function in women. J Sex Med. 2012 Jan;9(1):231-239.
  79. Fakhri A, Pakpour AH, Burri A, Morshedi H, Zeidi IM. The Female Sexual Function Index: Translation and Validation of an Iranian Version. J Sex Med. 2012;9(2):514-23.
  80. Fanfulla F, Camera A, Fulgoni P, Chiovato L, Nappi RE. Sexual dysfunction in obese women: does obstructive sleep apnea play a role?Sleep Med. 2013;14(3):252-256.
  81. Fantasia HC. Flibanserin and Female Sexual Desire. Nurs Women Health.. 2016 Jun-Jul;20(3):309-14.
  82. Farina B, Mazzotti E, Pasquini P, Mantione MG. Somatoform and psychoform dissociation among women with orgasmic and sexual pain disorders. J Trauma Dissociation. 2011;12(5):526-534.
  83. Farrell J, Cacchioni T. The medicalization of women's sexual pain. J Sex Res. 2012;49(4):328-336.
  84. Faubion SS, Parish SJ, Sexual Dysfunction In Women: Can We Talk About It? Cleve Clin J Med . 2017 May;84(5):367-376.
  85. Faubion SS, Rullo JE. Sexual Dysfunction in Women: A Practical Approach. Am Fam Physician . 2015 Aug;92(4):281-8.
  86. Faught B, Yuan J, Barbour K, Kissling R. Safety of Flibanserin in Premenopausal Women With Hypoactive Sexual Desire Disorder: Analysis of Phase 3, Placebo-Controlled Trials. Poster presented at: 20th Annual NPWH Premier Women's Healthcare Conference. October 13, 2017; Seattle, WA.
  87. Ferger B, Shimasaki M, Ceci A, Ittrich C, Allers KA, Sommer B. Flibanserin, a drug intended for treatment of hypoactive sexual desire disorder in pre-menopausal women, affects spontaneous motor activity and brain neurochemistry in female rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;381(6):573-579.
  88. Flibanserin (Addyi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2015;57(1478):133-135.
  89. Fisher W, Gruenwald I, Jannini E, Lev-Sagie A, Lowenstein L, Pyke R, Reisman Y, Revicki D, Rubio-Auiroles E. Standards for Clinical Trials in Male and Female Sexual Dysfunction: I. Phase I to Phase IV Clinical Trial Design. J Sex Med. 2016 Dec;13(12):1805-1817.
  90. Fisher W, Gruenwald I, Jannini E, Lev-Sagie A, Lowenstein L, Pyke R, Reisman Y, Revicki D, Rubio-Auiroles E. Standards for Clinical Trials in Male and Female Sexual Dysfunction: IV. Unique Aspects of Clinical Trials in Female Sexual Dysfunction. J Sex Med. 2017 Jan;14(1):19-26.
  91. Fisher WA, Pyke RE. Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder. Sex Med Rev . 2017 Oct;5(4):445-460.
  92. Flibanserin [briefing document]. Ingelheim am Rhein, Germany: Boehringer Ingelheim; May 14, 2010. Accessed July 17, 2013.
  93. Foley K, Foley D, Johnson BH. Healthcare resource utilization and expenditures of women diagnosed with hypoactive sexual desire disorder. J Med Econ. 2010;13(4):583-590.
  94. Fooladi E, Davis SR. An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother. 2012;13(15):2131-42.
  95. Frank JE, Mistretta P, Will J. Diagnosis and treatment of female sexual dysfunction. Am Fam Physician. 2008;77(5):635-642. 
  96. Gao Z, Yang D, Yu L, Cui Y. Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis. J Sex Med . 2015 Nov;12(11):2095-104.
  97. Gelez H, Greggain-Mohr J, Pfaus JG, Allers KA, Giuliano F. Flibanserin treatment increases appetitive sexual motivation in the female rat. J Sex Med. 2013;10(5):1231-9.
  98. Gellad WF, Flynn KE, Alexander GC. Evaluation of Flibanserin: Science and Advocacy at the FDA. JAMA. 2015;314(9):869-70.
  99. Gelman F, Atrio J. Flibanserin for hypoactive sexual desire disorder: place in therapy. Ther Adv Chronic Dis . 2017; Jan; 8(1):16-25.
  100. Gerstenberger EP, Rosen RC, Brewer JV, Meston CM, Brotto LA, Wiegel M, Sand M. Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010 Sep;7(9):3096-3103.
  101. Ghanbarzadeh M, Nadjafi-Semnani MR, Ghanbarzadeh MR, Nadjafi-Semnani A, Nadjfai-Semnani F. Female sexual dysfunction in Iran: study of prevalence and risk factors. Arch Gynecol Obstet. 2013;287(3):533-539.
  102. Giraldi A, Rellini A, Pfaus JG, Bitzer J, Laan E, Jannini EA, Fugl-Meyer AR. Questionnaires for assessment of female sexual dysfunction: a review and proposal for a standardized screener. J Sex Med. 2011;8(10):2681-2706.
  103. Giugliano F, Maiorino MI, Di Palo C, Autorino R, De Sio M, Giugliano D, Esposito K. Adherence to Mediterranean diet and sexual function in women with type 2 diabetes. J Sex Med. 2010;7(5):1883-1890.
  104. Goldfischer ER, Breaux J, Katz M, Kaufman J, Smith WB, Kimura T, Sand M, Pyke R. Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial. J Sex Med. 2011;8(11):3160-3172.
  105. Goldstein I, Fisher WA, Kim NN, Kingsberg, SA, Clayton AH, Sand M, Rosen RC, Goldstein SW. Thoughts on the U.S. Food and Drug Administration (FDA) Draft Guidance on Low Sexual Desire and Arousal. Sex Med Rev. 2017 Jan, 5(1): 1-2.
  106. Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R. Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Mayo Clin Proc . 2017 Jan;92(1):114-128.
  107. Goldstein I, Lines C, Pyke R, Scheld JS. National differences in patient-clinician communication regarding hypoactive sexual desire disorder. J Sex Med. 2009;6(5):1349-1357.
  108. Goldstein I. Current management strategies of the postmenopausal patient with sexual health problems. J Sex Med. 2007;4 Suppl 3:235-253.
  109. Goldstein SW, Goldstein I, Reflections of Women Successfully Treated by Flibanserin at a Single Center. J Sex Med. 2017 Jun. 14(6): 359.
  110. Grewal GS, Gill JS, Sidi H, Gurpreet K, Jambunathan ST, Suffee NJ, Midin M, Jaafar NR, Das S. Prevalence and risk factors of female sexual dysfunction among healthcare personnel in malaysia. Compr Psychiatry. 2013 Feb 26.
  111. Harsh V, McGarvey EL, Clayton AH. Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study. J Sex Med. 2008;5(3):640-645.
  112. Hartzband P, Groopman J. Untangling the Web—patients, doctors, and the Internet. N Engl J Med. 2010;362(12):1063-1066.
  113. Hawkes N. Do drugs have a role in turning indifference into passion? BMJ. 2010 5;341:c5532.
  114. Hatzichristou D, Kirana PS, Banner L, Althof SE, Lonnee-Hoffmann RA, Dennerstein L, Rosen RC. Diagnosing Sexual Dysfunction in Men and Women: Sexual History Taking and the Role of Symptom Scales and Questionnaires. J Sex Med . 2016 Aug;13(8):1166-82.
  115. Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril. 2007;87(1):107-112.
  116. Heiman JR, Rupp H, Janssen E, Newhouse SK, Brauer M, Laan E. Sexual desire, sexual arousal and hormonal differences in premenopausal US and Dutch women with and without low sexual desire. Horm Behav. 2011;59(5):772-779.
  117. Hernández Hernández JR, López-Tomassetti Fernández E, Caballero Díaz Y, Molina Cabrillana J, Morales García D, Núñez Jorge V.Remission of the female sexual dysfunction in morbidly obese female patients with the Scopinaro procedure. Surg Obes Relat Dis. 2013 Feb 28.
  118. Holloway V, Wylie K. Sex drive and sexual desire. Curr Opin Psychiatry. 2015;28(6):424-9.
  119. Hucker A, McCabe MP. Manualized Treatment Programs for FSD: Research Challenges and Recommendations. J Sex Med. 2011 Dec 21.
  120. Hylton V. Joffe, M.D., M.M.Sc., Christina Chang, M.D., M.P.H, Catherine Sewell, M.D., M.P.H, Olivia Easley, M.D., Christine Nguyen, M.D., Somya Dunn, M.D., Kimberly Lehrfeld, Pharm.D., LaiMing Lee, Ph.D., Myong-Jin Kim, Pharm.D., Ashley F. Slagle, Ph.D., and Julie Beitz, M.D. FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder. N Engl J Med . 2016; 374:101-104.
  121. Ibrahim ZM, Ahmed MR, Ahmed WA. Prevalence and risk factors for female sexual dysfunction among Egyptian women. Arch Gynecol Obstet. 2013;287(6):1173-80.
  122. Ishak IH, Low WY, Othman S. Prevalence, risk factors, and predictors of female sexual dysfunction in a primary care setting: a survey finding. J Sex Med. 2010;7(9):3080-3087.
  123. Isidori AM, Pozza C, Esposito K, Giugliano D, Morano S, Vignozzi L, Corona G, Lenzi A, Jannini EA. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010 Mar;7(3):1139-1146.
  124. Jacob KA, Bell J, Francis S. Resident training in female sexual dysfunction: a comparison of urology and obstetrics and gynecology programs. Female Pelvic Med Reconstr Surg. 2011;17(5):238-241.
  125. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. JAMA Intern Med . 2016 Apr;176(4):453-62.
  126. Jawed-Wessel S, Herbenick D, Schick V. The Relationship Between Body Image, Female Genital Self-Image, and Sexual Function Among First-Time Mothers. J Sex Marital Ther . 2017 Oct 3;43(7):618-632.
  127. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM, on behalf of the SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180-3188.
  128. Jayne CJ, Heard MJ, Zubair S, Johnson DL. New developments in the treatment of hypoactive sexual desire disorder – a focus on Flibanserin. Int J Womens Health . 2017 Apr 10;10;9:171-178.
  129. Jin J. Flibanserin for Treating Low Sexual Desire in Women. JAMA. 2015 Sep 22-29;314(12):1312.
  130. Jordan R, Edelson J, Greenberg S, Derogatis L, Kingsberg S, Rosen R, Althof S, Clayton A, Portman D, Krychman M. Efficacy of Subcutaneous Bremelanotide Self-Administed at Home by Premenopausal Women With Female Sexual Dysfunction: A Placebo-Controlled Dose-Ranging Study. Poster. International Society for the Study of Women’s Sexual Health Annual Meeting . 2013 Feb 28 – Mar 3.
  131. Juliato CRT, Melotti IGR, Junior LCS, Britto LGO, Riccetto CLZ. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction? Clinical Endocrinology News . 2017 Jun 13. pii: S1743-6095(17)31191-8.
  132. Kadioglu P, Yetkin DO, Sanli O, Yalin AS, Onem K, Kadioglu A. Obesity might not be a risk factor for female sexual dysfunction. BJU Int. 2010 Nov;106(9):1357-1361.
  133. Katz M, Derogatis LR, Ackerman R, Hedges P, Lesko L, Garcia M Jr, Sand M. Efficacy of Flibanserin in Women with Hypoactive Sexual Desire Disorder: Results from the BEGONIA Trial. J Sex Med. 2013;10(7):1807-1815.
  134. Kay GG, Hochadel T, Sicard E, Natarajan KK, Kim NN. Next-day residual effects of flibanserin on simulated driving performance in premenopausal women. Hum Psychopharmacol . 2017 Jul;32(4).
  135. Kennedy S. Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder. J Sex Med. 2010;7(10):3449-3459.
  136. Kim YH, Kim SM, Kim JJ, Cho IS, Jeon MJ. Does metabolic syndrome impair sexual function in middle- to old-aged women? J Sex Med. 2011;8(4):1123-1130.
  137. Kingsberg S. FDA addresses unmet need in drug development guidance for female sexual dysfunction. ObGyn News . 2016 Nov 8.
  138. Kingsberg S. Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2007;4(suppl 3):227-234.
  139. Kingsberg SA, Althof SE. Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction. J Sex Med. 2011;8(12):3262-3270.
  140. Kingsberg SA, Althof S, Simon JA, Bradford A, Bitzer J, Carvalho J, Flynn KE, Nappi RE, Reese JB, Rezaee RL, Schover L, Shifrin JL. Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14. J Sex Med . 2017 Dec;14(12):1463-1491.
  141. Kingsberg SA, Clayton AH, Pfaus JG. The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder. CNS Drugs. 2015 Nov;29(11):915-33.
  142. Kingsberg S, Derogatis L, Edelson J, Jordan R, Krychman M. Distress Reduction in Female Sexual Dysfunctions: A Dose-Ranging Study of Subcutaneous Bremelanotide. Poster. Clinical Meeting of the American College of Obstetricians and Gynecologists . 2014 Apr 26-30.
  143. Kingsberg SA, Rezaee RL. Hypoactive sexual desire in women. Menopause. 2013;20(12):1284-300.
  144. Kingsberg SA, Simon JA, Goldstein I. The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med . 2008 Sep 2;5 Suppl 4:182-93; quiz 193.
  145. Kingsberg SA, Woodard T. Female Sexual Dysfunction: Focus on Low Desire. Obstet Gynecol . 2015 Feb.125(2):477-86.
  146. Kingsberg SA. Identifying HSDD in the family medicine setting. J Fam Pract. 2009;58(7 Suppl Hypoactive):S22-25.
  147. Kornstein SG, Simon JA, Apfel SC, Yuan J, Barbour KA, Kissling R. Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis. . J Womens Health (Larchmt) . 2017 Nov;26(11):1161-1168.
  148. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537-544.
  149. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause. 2006;13(1):46-56.
  150. Lenzer J. Boehringer Ingelheim withdraws libido drug for women. BMJ. 2010 Oct 12;341:c5701.
  151. Levine SB. Flibanserin. Arch Sex Behav. 2015 Nov;44(8):2107-9.
  152. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762-774.
  153. Lodise NM. Female sexual dysfunction: a focus on flibanserin. Int J Womens Health . 2017 Oct 11;9:757-767..
  154. Lodise NM. Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health. Pharmacotherapy. 2013;33(4):411-421.
  155. Lorenz T, Rullo J, Faubion S. Antidepressant-Induced Female Sexual Dysfunction. Mayo Clin Proc . 2016 Sep;91(9):1280-6.
  156. Lucas J; DeRogatis LR; Jordan R. A Placebo-Controlled, Randomized, Double-Blind, Three Period, Three-Way Crossover Study on the Hemodynamic and Pharmacokinetic Interactions of Bremelanotide and Ethanol. Palatin Technologies, USA; 2: Maryland Center for Sexual Health, USA .
  157. Margo K, Winn R. Testosterone treatments: why, when, and how? Am Fam Physician. 2006;73(9):1591-1598.
  158. Martelli V, Valisella S, Moscatiello S, Matteucci C, Lantadilla C, Costantino A, Pelusi G, Marchesini G, Meriggiola MC. Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic Syndrome. J Sex Med. 2012;9(2):434-441.
  159. Martelli V, Valisella S, Moscatiello S, Matteucci C, Lantadilla C, Costantino A,  Pelusi G, Marchesini G, Meriggiola MC. Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med. 2012;9(2):434-441
  160. Martinez L. The proactive sexual health history. Am Fam Physician. 2002;66(9):1705-1712.
    Link
  161. Maserejian NN, Parish S, Shifren JL, Huang L, Gerstenberger E, Rosen RC. Healthcare utilization in women diagnosed with hypoactive sexual desire disorder: interim baseline results from the HSDD Registry for Women. J Womens Health (Larchmt). 2010;19(11):2001-2009.
  162. Maserejian NN, Shifren J, Parish SJ, Segraves RT, Huang L, Rosen RC. Sexual arousal and lubrication problems in women with clinically diagnosed hypoactive sexual desire disorder: preliminary findings from the hypoactive sexual desire disorder registry for women. J Sex Marital Ther. 2012;38(1):41-62.
  163. Maserejian NN, Shifren JL, Parish SJ, Braunstein GD, Gerstenberger EP, Rosen RC. The presentation of hypoactive sexual desire disorder in premenopausal women. J Sex Med. 2010;7(10):3439-3448.
  164. McCabe MP, Goldhammer DL. Prevalence of Women's Sexual Desire Problems: What Criteria Do We Use? Arch Sex Behav. 2013;42(6):1073-1078.
  165. McCabe MP, Jones LM. Attrition from an Internet-based treatment program for female sexual dysfunction: Who is best treated with this approach? Psychol Health Med. 2013 Jan 31.18:612-618.
  166. McCabe M, Jones L, Attrition from an Internet-base treatment program for female sexual dysfunction: Who is best treated with this approach? J of Psych . 2012 Aug; 612-618.
  167. McCool ME, Zuelke A, Theurich MA, Knuettel H, Ricci C, Apfelbacher C. Prevalence of Female Sexual Dysfunction Among Premenopausal Women: A Systematic Review and Meta-Analysis of Observational Studies. Sex Med Rev . 2016 Jul;4(3):197-212.
  168. Mendonca CR, Arruda JT, Noll M, Campoli PMO, Amaral WND. Sexual dysfunction in infertile women: A systematic review and meta-anaylsis. Eur J Obstet Gynecol Reprod Biol . 2017 Jun 7;215:153-163.
  169. Meston, C, Derogatis L. Validated Instruments for Assessing Female Sexual Function. J Sex Marital Ther . 2002;28 Suppl 1:155-64.
  170. Miner M, Esposito K, Guay A, Montorsi P, Goldstein I. Cardiometabolic risk and female sexual health: the Princeton III summary. J Sex Med. 2012;9(3):641-652.
  171. Miner M, Sadovsky R, Buster JE. Hypoactive sexual desire disorder in premenopausal women: case studies.Postgrad Med. 2012;124(1):94-103.
  172. Moore RH, Sarwer DB, Lavenberg JA, Lane IB, Evans JL, Volger S, Wadden TA. Relationship between sexual function and quality of life in obese persons seeking weight reduction. Obesity (Silver Spring). 2013 Mar 20;(10):1966-1974
  173. Moynihan R. FDA panel rejects testosterone patch for women on safety grounds. BMJ. 2004; 329(7479):1363.
  174. Muniyappa R, Norton M, Dunn ME, Banerji MA. Diabetes and female sexual dysfunction: moving beyond "benign neglect ". Curr Diab Rep. 2005 Jun; 5(3):230-6.
  175. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27(1):39-48
  176. Nappi RE. Why are there no FDA-approved treatments for female sexual dysfunction? Expert Opin Pharmacother. 2015;16(12):1735-8.
  177. Nappi RE, Albani F, Santamaria V, Tonani S, Martini E, Terreno E, Brambilla E, Polatti F. Menopause and sexual desire: the role of testosterone. Menopause Int. 2010;16(4):162-168.
  178. Nappi R, Cucinella L, Tiranini L, Martini E. Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics? Taylor and Francis. 2007 Oct; 19(5):421-423.
  179. Nappi RE, Martini E, Terreno E, Albani F, Santamaria V, Tonani S, Chiovato L, Polatti F. Management of hypoactive sexual desire disorder in women: current and emerging therapies. Int J Womens Health. 2010;2:167-175.
  180. Nappi RE, Wawra K, Schmitt S. Hypoactive sexual desire disorder in postmenopausal women. Gynecol Endocrinol . 2006 Jun;22(6):318-23.
  181. Nowosielski K, Drosdzol A, Sipiñski A, Kowalczyk R, Skrzypulec V. Diabetes mellitus and sexuality--does it really matter? J Sex Med. 2010;7(2 Pt 1):723-735.
  182. Nowosielski K, Wróbel B, Sioma-Markowska U, Poreba R. Sexual dysfunction and distress--development of a Polish version of the female sexual distress scale-revised. J Sex Med. 2013;10(5):1304-1312.
  183. Nowosielski K, Wróbel B, Sioma-Markowska U, Poreba R. Development and validation of the Polish version of the Female Sexual Function Index in the Polish population of females. J Sex Med. 2013;10(2):386-395.
  184. O'Loughlin JI, Basson R, Brotto LA. Women With Hypoactive Sexual Desire Disorder versus Sexual Interest/Arousal Disorder: An Empirical Test of Raising the Bar. J Sex Res . 2017 Nov 2:1-13.
  185. Osborne V, Hazell L, Layton D, Shakir SA. Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management. Drug Saf. 2010;33(3):213-221.
  186. Pakpour AH, Yekaninejad MS, Zeidi IM, Burri A. Prevalence and risk factors of the female sexual dysfunction in a sample of infertile Iranian women. Arch Gynecol Obstet. 2012;286(6):1589-1596.
  187. Palacios S. Hypoactive Sexual Desire Disorder and current pharmacotherapeutic options in women. Womens Health (Lond Engl). 2011;7(1):95-107.
  188. Palatin Technologies, Inc. www.palatin.com/programs/female-sexual-dysfunction.
  189. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, Rees M, Rodenberg CA, Rymer J, Schwenkhagen A, Sturdee DW. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13(2):121-131.
  190. Parish S, Montefiore Medical Center, Bronx, NY, oral responses to in-depth physician interview, July 21, 2009.
  191. Parish SJ, Hahn SR. Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment. Sex Med Rev . 2016 Apr;4(2):103-120.
  192. Parish S, Hahn S. The Epidemiology and Diagnosis of Hypoactive Sexual Desire Disorder and Causes of HSDD: Situational, Depression, Drugs, Chronic Illnesses, and Hormonal Depletion. J Sex Med . 2016 Apr.4(2):103-120.
  193. Parish SJ, Goldstein AT, Goldstein SW, Goldstein I, Pfaus J, Clayton AH, Giraldi A, Simon JA, Althof SE, Bachmann G, Komisaruk B, Levin R, Spadt SK, Kingsberg SA, Perelman MA, Waldinger MD, Whipple B. Toward a More Evidence-Based Nosology and Nomenclature for Female Sexual Dysfunctions-Part II. J Sex Med . 2016 Dec 13. (12):1888-1906.
  194. Pasquali D, Maiorino MI, Renzullo A, Bellastella G, Accardo G, Esposito D, Barbato F, Esposito K. Female sexual dysfunction in women with thyroid disorders.J Endocrinol Invest. 2013 Apr 12. 36(9):729-33.
  195. Pauls RN, Kleeman SD, et al. Practice patterns of physician members of the American Urogynecologic Society regarding female sexual dysfunction: results of a national survey.Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(6):460-467.
  196. Pauls RN, Kleeman SD, Segal JL, Silva WA, Goldenhar LM, Karram MM. Practice patterns of physician members of the American Urogynecologic Society regarding female sexual dysfunction: results of a national survey. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16(6):460-467.
  197. Perelman M. Why the Sexual Tipping Point Is a “Variable Switch Model”. Curr Sex Health Rep 2018;10(2):38-43.
  198. Petherick A, Sexual arousal: Sex matters. Nature . 2017 Oct 4;550(7674):S2-S3.
  199. Poels S, Bloemers J, Van Rooij K, Goldstein I, Gerritsen J, Van Ham D, Van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A. Toward Personalized Sexual Medicine (Part 2): Testosterone Combined with PDE5 Inhibitor Increases Sexual Satisfaction in Women with HSDD and FSAD, and a Low Sensitive System for Sexual Cues. J Sex Med . 2013 Mar;10(3);810-823.
  200. Poels S, Bloemers J, van Rooij K, Koppeschaar H, Olivier B, Tuiten A. Two novel combined drug treatments for women with hypoactive sexual desire disorder. Pharmacol Biochem Behav. 2014;121:71-79.
  201. Polland A, Davis M, Zeymo A, Venkatesan K. Comparison of Correlated Comorbidities in Male and Female Sexual Dysfunction: Findings From the Third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). J Sex Med. 2018 Apr.
  202. Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: a systematic review and meta-analysis. J Sex Med. 2013;10(4):1044-1051.
  203. Portman D, Brown L, Yuan J, Kissling R, Kingsberg S. Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study. J Sex Med. 2017 Jun;14(6):834-842.
  204. Portman D, Edelson J, Jordan R, Clayton A, Krychman M, Bremelanotide for Hypoactive Sexual Desire Disorder: Analyses From a Phase 2B Dose-Ranging Study. Poster. Clinical Meeting of the American College of Obstetricians and Gynecologists . 2014 Apr 26-30.
  205. Pyke RE, Clayton AH. Assessment of Sexual Desire for Clinical Trials of Women With Hypoactive Sexual Desire Disorder: Measures, Desire-Related Behavior, and Assessment of Clinical Significance. Sex Med Rev. 2018 Jan; 19.
  206. Pyke RE, Clayton AH. Effect Size in Efficacy Trials of Women With Decreased Sexual Desire. Sex Med Rev. 2018 Mar.
  207. Revicki DA, Atlhof S, DeRogatis L, Wilson H, Lucas J. Reliability and Validity of the Elements of Desire Questionnaire in the Bremelanotide RECONNECT study. J Sex Med. 2017. 14(6)5: 364-365.
  208. Revicki DA, Margolis MK, Bush EN, DeRogatis LR, Hanes V. Content validity of the Female Sexual Function Index (FSFI) in pre- and postmenopausal women with hypoactive sexual desire disorder. J Sex Med. 2011;8(8):2237-2245.
  209. Reviriego C. Flibanserin for female sexual dysfunction. Drugs Today (Barc). 2014;50(8):549-56.
  210. Robinson K, Cutler JB, Carris NW. First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin. Ann Pharmacother . 2016 Feb;50(2):125-32.
  211. Rochester-Eyeguokan C, Meade L. A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes. Diabetes Ther . 2017 Oct;8(5):991-998.
  212. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R. The female sexual function index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208.
  213. Rosen RC, Connor MK, Miyasato G, Link C, Shifren JL, Fisher WA, Derogatis LR, Schobelock MJ. Sexual Desire Problems in Women Seeking Healthcare: A Novel Study Design for Ascertaining Prevalence of Hypoactive Sexual Desire Disorder in Clinic-Based Samples of U.S. Women. J Womens Health (Larchmt). 2012 May 21. (5):505-15.
  214. Rosen RC, Maserejian NN, Connor MK, Krychman ML, Brown CS, Goldstein I. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Menopause. 2012 Apr 19.(4):396-405.
  215. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009;6(6):1549-1560.
  216. Ryding EL, Blom C. Validation of the Swedish version of the Female SexuaL Function Index (FSFI) in women with hypoactive sexual desire disorder. J Sex Med. 2015;12(2):341-9.
  217. Sadovsky R, Alam W, Enecilla M, Cosiquien R, Tipu O, Etheridge-Otey J. Sexual problems among a specific population of minority women aged 40-80 years attending a primary care practice. J Sex Med. 2006;3(5):795-803.
  218. Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med . 2008 Apr;5(4):887-97.
  219. Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 2010;106(6):832-839.
  220. Shaeer O, Shaeer K, Shaeer E. The Global Online Sexuality Survey (GOSS): Female Sexual Dysfunction among Internet Users in the Reproductive Age Group in the Middle East. J Sex Med. 2012 ;9(2):411-24.
  221. Shahar MA, Hussein H, Sidi H, Shah SA, Mohamed Said MS. Sexual dysfunction and its determinants in Malaysian women with rheumatoid arthritis. Int J Rheum Dis. 2012;15(5):468-77.
  222. Shapiro D, Stevens D, Stahl SM. Flibanserin – The Female Viagra? Int J Psychiatry Clin Pract. 2017 Apr 24:1-7.
  223. Shi YF, Shao XY, Lou QQ, Chen YJ, Zhou HJ, Zou JY. Study on female sexual dysfunction in type 2 diabetic Chinese women. Biomed Environ Sci. 2012;25(5):557-561.
  224. Shifren JL, Johannes CB, Monz BU, Russo PA, Bennett L, Rosen R. Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt). 2009;18(4):461-468.
  225. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112(5):970-978.
  226. Simon J, Brown L, Yuan J, Spigelman S. Evaluation of Clinical Meaningfulness in the Flibanserin HSDD Clinical Development Program. J Sex Med. 2016 13(6) S245.
  227. Simon J, Brown L, Yuan J. Spigelman, S. Evaluation of Clinical Meaningfulness in the Flibanserin, HSDD Clinical Development Program. 1: George Washington University and Women’s Health and Research Consultants; 2: Sprout Pharmaceuticals, Inc. USA; 3: Valeant Pharmaceuticals, Inc, USA 2016.
  228. Simon JA, Derogatis L, Portman D, Yuan J, Kissling R. Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study. J Sex Med. 2018 Mar;15(3):387-395.
  229. Simon JA, Goldstein I, Kim NN, Freedman MA, Parish SJ. Flibanserin Approval: Facts or Feelings? J Sex Med . 2016 Jun;4(2):e69-e70.
  230. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desiredisorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633-640.
  231. Simon J, Portman D, Kingsberg S, Clayton A, Jordan R, Lucas J, Spana C. Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD) in RECONNECT Study: Efficacy Analysis in Study Completers Responders. 1: Washington University and Women’s Health and Research Consultants, Washington, DC, USA; 2: Columbus Centter for Women’s Health Research, Columbus, OH, USA; 3: University Hospitals Case Medical Center, Cleveland, OH, USA; 4: University of Virginia, Charlottesville, VA, USA; 5: Palatin Technologies, Cranbury, NJ, USA June 2017.
  232. Simon JA, Yuan J, Barbour KA, Kissling R. Flibanserin in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Responder Analysis of Randomized Placebo-Controlled Studies. J Sex Med. 2017 Jun. 14(6): 355.
  233. Simon JA. Low sexual desire--is it all in her head? Pathophysiology, diagnosis, and treatment of hypoactive sexual desire disorder. Postgrad Med. 2010;122(6):128-136. Review.
  234. Snabes MC, Simes SM. Approved hormonal treatments for HSDD: an unmet medical need. J Sex Med. 2009;6(7):1846-1849.
  235. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8(1):15-27.
  236. Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015;20(1):1-6.
  237. Stahl SM. Targeting circuits of sexual desire as a treatment strategy for hypoactive sexual desire disorder. J Clin Psychiatry. 2010;71(7):821-822.
  238. Strecker K, Adamaszek M, Ohm S, Wegner F, Beck J, Schwarz J. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. J Neural Transm. 2012;119(11):1351-9.
  239. Symonds T, Abraham L, Bushmakin AG, Williams K, Martin M, Cappelleri JC. Sexual function questionnaire: further refinement and validation. J Sex Med . 2012;9(10):2609-2616.
  240. Terrier C, Terrier JE. [Efficacy and safety of flibanserin "new female Viagra®? ": Literature review]. Prog Urol . 2016 Sep - Oct;26(11-12):592-599.
  241. Thorp J Jr, Palacios S, Symons J, Simon J, Barbour K. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG. 2014;121(11):1328-1331.
  242. Thorp J, Simon J, Dattani D, Taylor L, Kimura T, Garcia M Jr, Lesko L, Pyke R. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793-804.
  243. Trocóniz IF, Boland K, Staab A. Population Pharmacokinetic/Pharmacodynamic Model for the Sedative Effects of Flibanserin in Healthy Volunteers. Pharm Res. 2012;29(6):1518-29.
  244. Vallejos X, Wu C. Flibanserin. J Pharm Pract . 2017 Apr;30(2):256-260.
  245. van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A. Toward personalized sexual medicine (part 3): testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. J Sex Med. 2013;10(3):824-837.
  246. Varghese KM, Bansal R, Kekre AN, Jacob KS. Sexual dysfunction among young married women in southern India. Int Urogynecol J. 2012;23(12):1771-1774.
  247. Veronelli A, Mauri C, Zecchini B, et al. Sexual dysfunction is frequent in premenopausal women with diabetes, obesity, and hypothyroidism, and correlates with markers of increased cardiovascular risk: a preliminary report. J Sex Med. 2009;6(6):1561-1568.
  248. Wallwiener CW, Wallwiener LM, Seeger H, Mück AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med. 2010;7(6):2139-2148.
  249. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168(13):1441-1449.  
  250. White WB, Grady D, Giudice LC, Berry SM, Zborowski J, Snabes MC. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J. 2012;163(1):27-32.
  251. Wing RR, Bond DS, Gendrano IN 3rd, Wadden T, Bahnson J, Lewis CE, Brancati F, Schneider S, Kitabchi AE, Van Dorsten B, Rosen RC. Effect of Intensive Lifestyle Intervention on Sexual Dysfunction in Women With Type 2 Diabetes: Results from an ancillary Look AHEAD study. The Sexual Dysfunction Subgroup of the Look AHEAD Research Group. Diabetes Care. 2013 Jun 11.
  252. Woodard TL, Nowak NT, Balon R, Tancer M, Diamond MP. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril. 2013 Jul 2.
  253. Woodis CB, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy. 2012;32(1):38-53.
  254. Worsley R, Bell RJ, Gartoulla P, Davis SR. Prevalence and Predictors of Low Sexual Desire, Sexually Related Personal Distress, and Hypoactive Sexual Desire Dysfunction in a Community-Based Sample of Midlife Women. J Sex Med . 2017 May;14(5):675-686.
  255. Wyllie MG. Resurgence of interest in sexual dysfunction? BJU Int. 2012;109(11):E36-7.
  256. Yaylali GF, Tekekoglu S, Akin F. Sexual dysfunction in obese and overweight women. Int J Impot Res. 2010;22(4):220-226.
  257. Zhang H, Yip PS. Female sexual dysfunction among young and middle-aged women in Hong Kong: prevalence and risk factors. J Sex Med. 2012;9(11):2911-2918.